Tiratricol
OTHER NAME(S): Acide 3,3', 5-Triiodothyroacétique, Acide Triiodothyroacétique, T-cuts, Triac, Triax, Tricana, Triiodothyroacetic Acid, 3,3',5-triiodothyroacetic acid
Overview
Tiratricol is a thyroid hormone that occurs naturally in the body. It can also be made in a lab and taken by mouth under the supervision of a healthcare provider.
Tiratricol can alter thyroid function. It should not be used without medical supervision. In France, tiratricol is a prescription drug. In the US, tiratricol is not legal to include in dietary supplements. The US FDA has warned against the use of products containing tiratricol.
People use tiratricol for thyroid disorders, high cholesterol, and other conditions, but there is no good scientific evidence to support these uses. It may also be unsafe.
Uses
We currently have no information for Tiratricol overview.
Side Effects
When taken by mouth: Tiratricol is possibly safe when used under the supervision of a healthcare provider for specific medical purposes. It can cause side effects such as diarrhea, fatigue, and weakness. Tiratricol is possibly unsafe to use without medical supervision. It can cause serious adverse effects such as rapid heart rate, shakiness, anxiety, and weight loss.
Precautions
When taken by mouth: Tiratricol is possibly safe when used under the supervision of a healthcare provider for specific medical purposes. It can cause side effects such as diarrhea, fatigue, and weakness. Tiratricol is possibly unsafe to use without medical supervision. It can cause serious adverse effects such as rapid heart rate, shakiness, anxiety, and weight loss.
Pregnancy: Tiratricol is possibly safe when taken by mouth under the supervision of a healthcare provider for the treatment of thyroid problems in the developing infant. Tiratricol is likely unsafe when taken by mouth without medical supervision because it might harm the developing infant's heart.
Breast-feeding: There isn't enough reliable information to know if tiratricol is safe to use when breast-feeding. Stay on the safe side and avoid use.
Diabetes: Tiratricol might interfere with blood sugar control. Doses of medications used to treat diabetes might need to be adjusted. If you have diabetes, speak with a healthcare provider before taking tiratricol.
Heart disease: Taking tiratricol might worsen symptoms of heart disease. Avoid use.
Interactions
Moderate Interaction
Be cautious with this combination
- Cholestyramine (Questran) interacts with TiratricolCholestyramine might decrease how much tiratricol the body absorbs. This might decrease the effects of tiratricol. To avoid this interaction, take tiratricol at least one hour before or four hours after taking cholestyramine.
- Medications for diabetes (Antidiabetes drugs) interacts with TiratricolTiratricol might lower blood sugar levels. Taking tiratricol along with diabetes medications might cause blood sugar to drop too low. Monitor your blood sugar closely.
- Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with TiratricolTiratricol might slow blood clotting. Taking tiratricol along with medications that also slow blood clotting might increase the risk of bruising and bleeding.
- Thyroid hormone interacts with TiratricolTiratricol works similarly to thyroid hormones. Taking tiratricol along with thyroid hormone pills might increase the chance of side effects from thyroid hormone.
Dosing
There isn't enough reliable information to know what an appropriate dose of tiratricol might be. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult a healthcare professional before using.
References
- McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
- US Food and Drug Administration (FDA). Dietary Supplements Containing Tiratricol: FDA Warns Consumers Against Consuming Tiratricol. Potent Thyroid Hormone Promoted as Dietary Supplement, Nov 21, 2000. Available at: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/enforcement-story-archive/center-food-safety-and-applied-nutrition-continued-2001-0
- McDermott MT, Ridgway EC. Central hyperthyroidism. Endocrinol Metab Clin North Am 1998;27:187-203.
- Takeda T, Suzuki S, Liu RT, et al. Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J Clin Endocrinol Metab 1995;80:2033-40.
- Kunitake JM, Hartman N, Henson LC, et al. 3,5,3'-triiodothyroacetic acid therapy for thyroid hormone resistance. J Clin Endocrinol Metab 1989;69:461-6.
- Dulgeroff AJ, Geffner ME, Koyal SN, et al. Bromocriptine and Triac therapy for hyperthyroidism due to pituitary resistance to thyroid hormone. J Clin Endocrinol Metab 1992;75:1071-5.
- Beck-Peccoz P, Sartorio A, De Medici C, et al. Dissociated thyromimetic effects of 3, 5, 3'-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels. J Endocrinol Invest 1988;11:113-8.
- Lind P, Langsteger W, Koltringer P, et al. 3,5,3'-Triiodothyroacetic acid (TRIAC) effects on pituitary thyroid regulation and on peripheral tissue parameters. Nuklearmedizin 1989;28:217-20.
- Nicolini U, Venegoni E, Acaia B, et al. Prenatal treatment of fetal hypothyroidism: is there more than one option? Prenat Diagn 1996;16:443-8.
- Asteria C, Rajanayagam O, Collingwood TN, et al. Prenatal diagnosis of thyroid hormone resistance. J Clin Endocrinol Metab 1999;84:405-10.
- Radetti G, Persani L, Molinaro G, et al. Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid 1997;7:775-8.
- Jaffiol C, Daures JP, Nsakala N, et al. [Long term follow up of medical treatment of differentiated thyroid cancer]. Ann Endocrinol (Paris) 1995;56:119-26.
- Mueller-Gaertner HW, Schneider C. 3,5,3'-Triiodothyroacetic acid minimizes the pituitary thyrotrophin secretion in patients on levo-thyroxine therapy after ablative therapy for differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 1988;28:345-51.
- Mechelany C, Schlumberger M, Challeton C, et al. TRIAC (3,5,3'-triiodothyroacetic acid) has parallel effects at the pituitary and peripheral tissue levels in thyroid cancer patients treated with L-thyroxine. Clin Endocrinol (Oxf) 1991;35:123-8.
- Chow WS, Lam KS. An overweight woman with galactorrhoea. Postgrad Med J 1998;74:121-2.
- Lledo Carreres M, Lajo Garrido JL, Gonzalez Rico M, et al. Toxic internuclear ophthalmoplegia related to antiobesity treatment. Ann Pharmacother 1992;26:1457-8.
- Ferner RE, Burnett A, Rawlins MD. Triiodothyroacetic acid abuse in a female body builder. Lancet 1986;1:383.
- Heim J. [Hypothyroidism of central origin corrected by the cessation of Triac therapy]. Ann Med Interne (Paris) 1982;133:588-9.
- Jean-Pastor MJ, Jean P, Biour M, et al. [Hepatopathies from treatment with a specialty drug combination of tiratricol-cyclovalone-retinol]. J Toxicol Clin Exp 1986;6:115-21.
- Bentin J, Desir D, Mockel J. Triac (3,5,3'-triiodo-thyroacetic acid) induced "pseudohypothyroidism". Acta Clin Belg 1984;39:285-9.
- Hawkey CM, Olsen EG, Symons C. Production of cardiac muscle abnormalities in offspring of rats receiving triiodothyroacetic acid (triac) and the effect of beta adrenergic blockade. Cardiovasc Res 1981;15:196-205.
- Olsen EG, Symons C, Hawkey C. Effect of triac on the developing heart. Lancet 1977;2:221-3.
- Pitt-Rivers R. Physiological activity of the acetic acid analogues of some iodinated thyronines. Lancet 1953;2:234.
- Lerman JL, Pitt-rivers R. Physiological activity of triiodo and tetraiodothyroacetic acid on blood-cholesterol levels. Lancet 1956;1:885-9.
- Menegay C, Juge C, Burger AG. Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. Acta Endocrinol (Copenh) 1989;121:651-8.
- Sherman SI, Ringel MD, Smith MJ, et al. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J Clin Endocrinol Metab 1997;82:2153-8.
- Sherman SI, Ladenson PW. Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects. J Clin Endocrinol Metab 1992;75:901-5.
- Bracco D, Morin O, Schutz Y, et al. Comparison of the metabolic and endocrine effects of 3,5,3'-triiodothyroacetic acid and thyroxine. J Clin Endocrinol Metab 1993;77:221-8.
- Anon. FDA warns against consuming dietary supplements containing tiratricol. FDA. 2000. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS01057.html
- Scally MC, Hodge A. A report of hypothyroidism induced by an over-the-counter fat loss supplement (Tiratricol). Int J Sport Nutr Exerc Metab 2003;13(1):112-6.
- Bauer BA, Elkin PL, Erickson D, Klee GG, Brennan MD. Symptomatic hyperthyroidism in a patient taking the dietary supplement tiratricol. Mayo Clin Proc 2002;77(6):587-90.
- Cohen-Lehman J, Charitou MM, Klein I. Tiratricol-induced periodic paralysis: a review of nutraceuticals affecting thyroid function. Endocr Pract 2011;17(4):610-5.
- Chan SL, Refetoff S, Babic N, Jin M, Garg U, Yeo KJ. Triiodothyroacetic Acid Cross-Reacts With Measurement of Triiodothyronine (T3) on Various Immunoassay Platforms. Am J Clin Pathol 2021.
- van Geest FS, Groeneweg S, van den Akker ELT, et al. Long-Term Efficacy of T3 Analogue Triac in Children and Adults With MCT8 Deficiency: A Real-Life Retrospective Cohort Study. J Clin Endocrinol Metab 2022;107(3):e1136-e1147.
- American Thyroid Association. ATA Supports FDA Warning on Triax; February 26, 2000. Available at: https://www.thyroid.org/ata-supports-fda-warning-on-triax/
- Grijota-Martínez C, Montero-Pedrazuela A, Hidalgo-Álvarez J, Bárez-López S, Guadaño-Ferraz A. Intracerebroventricular High Doses of 3,3',5-Triiodothyroacetic Acid at Juvenile Stages Improve Peripheral Hyperthyroidism and Mediate Thyromimetic Effects in Limited Brain Regions in a Mouse Model of Monocarboxylate Transporter 8 Deficiency. Thyroid 2023;33(4):501-510.
- Chen J, Salveridou E, Liebmann L, et al. Triac Treatment Prevents Neurodevelopmental and Locomotor Impairments in Thyroid Hormone Transporter Mct8/Oatp1c1 Deficient Mice. Int J Mol Sci 2023;24(4):3452.